Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)

People with advanced triple-negative breast cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

You may be eligible to participate in this study if you:

• Are at least 18 years of age
• Have inoperable, locally advanced, or metastatic breast cancer
• Have histologically confirmed HR-positive/HER2-negative breast cancer
• Have inoperable, locally advanced, or metastatic TNBC
• Have known brain metastases
• Have archival or fresh tumor tissue
• Have received at least 1 but no more than 3 prior systemic lines of treatment regimens
• Have known central nervous system lesions

You may NOT participate in this study if you:

• Have history of malignancy that is active within the previous 2 years
• Have untreated symptomatic or untreated known brain and/or leptomeningeal metastases
• Have active or chronic corneal disorder
• Have a significant cardiac disease
• Have had major surgery within 3 months prior to dosing.
• Have known immunodeficiency virus (HIV) infection, hepatitis B, or C
• Are pregnant or breastfeeding

Contact Information
Ana Maria Bernal Guarin, Study Coordinator
1695 Eastchester Road, Bronx, New York 10461
Phone: (718) 405-8428